Chronic obstructive pulmonary disease (COPD) is a persistent and progressive disorder characterized by airway or alveolar abnormalities, commonly leading to pulmonary hypertension (PH).
I am writing this as I return from a conference of over 10,000 professionals dedicated primarily to the research and clinical care of respiratory disease.
Webinar presentations: Autoantibodies as the cause of PAH; Prevalence and effect of myelofibrosis on PAH; Mast cells as the cause of pulmonary vascular remodelling in PAH; B-cell depletion with rituximab for the treatment of systemic sclerosis-associated PH; Emergency myelopoiesis contributes to immune cell exhaustion in pulmonary vascular remodelling
Pulmonary arterial hypertension (PAH) is a poorly understood disease of the small pulmonary arteries. Pulmonary vascular remodeling and progressively rising pulmonary vascular resistance are hallmarks of the disease that ultimately result in right heart failure.
We aimed to describe the clinical characteristics, healthcare resource utilization (HCRU) and costs, health-related quality of life (HRQoL), and survival for patients with pulmonary arterial hypertension (PAH), stratified by 1-year mortality risk at diagnosis.
Over 80 Mio people worldwide live >2500 m, including at least as many patients with pulmonary vascular disease (PVD), defined as pulmonary arterial or chronic thromboembolic pulmonary hypertension (PAH/CTEPH), as elsewhere (estimated 0.1‰).
Children with pulmonary hypertension (PH) often demonstrate limited exercise capacity. Data support exercise as an effective nonpharmacologic intervention among adults with PH.
